Long-term Efficacy of Bendamustine

Following bendamustine, stem cell collection was successful in 9 of 12 patients at a median time to collection of 12.5 months. In the setting of relapsed/refractory NHL, this was similar to published rates and “consistent with the low rate of collection failure following bendamustine in a prospective trial,” the authors indicated.

Continue Reading

Following bendamustine therapy, 80 patients had disease progression and 98 received subsequent therapies, including 31 whose disease did not progress; 93 patients died.

Median event-free survival (EFS) was 14.1 months; EFS was 28.1% at 2 years and 19.8% at 5 years. Median EFS was 9.9 months for patients receiving single agent bendamustine and 33.8 months for patients receiving bendamustine in combination.

Median overall survival (OS) after bendamustine treatment was 65.9 months and was associated with histology, with median survival being longest for patients with follicular lymphoma (84.9 months) and lowest for transformed lymphoma (7.0 months).

Median OS was 44.9 months for patients receiving single agent bendamustine and 113.2 months for patients receiving bendamustine in combination.

“afety of bendamustine in the relapsed/refractory setting,” Dr Khan said. er treatments after bendamustine therapy, which speaks to the erapies following bendamustine, the be They cautioned, however, that these results do not support first-line use of bendamustine.

RELATED: Despite Improvements, Survival Disparities Persist for Childhood Leukemia

“It is challenging to evaluate long-term efficacy and toxicity for an anti-lymphoma agent in the relapsed/refractory setting since patients receive multiple lines of therapy,” Dr Martin said. He added that some patients died from lymphoma or from treatment-related toxicities, which is “why the long-term follow up is limited to a smaller patient population.”

Other studies will be required to show whether bendamustine is safe in the front-line setting.


  1. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204-10.
  2. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4473-9.
  3. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Cancer. 2010;116:106-14.
  4. Martin P, Chen Z, Cheson BD, et al. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. Br J Haematol. 2017 Apr 17. doi: 10.1111/bjh.14667 [Epub ahead of print]